1962 related articles for article (PubMed ID: 11217867)
21. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
David SR; Taylor CC; Kinon BJ; Breier A
Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
[TBL] [Abstract][Full Text] [Related]
22. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
Gureje O; Miles W; Keks N; Grainger D; Lambert T; McGrath J; Tran P; Catts S; Fraser A; Hustig H; Andersen S; Crawford AM
Schizophr Res; 2003 Jun; 61(2-3):303-14. PubMed ID: 12729882
[TBL] [Abstract][Full Text] [Related]
23. Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.
Bever KA; Perry PJ
Am J Health Syst Pharm; 1998 May; 55(10):1003-16. PubMed ID: 9606451
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
25. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
[TBL] [Abstract][Full Text] [Related]
26. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Bounthavong M; Okamoto MP
J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
[TBL] [Abstract][Full Text] [Related]
27. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.
Palmer CS; Brunner E; Ruíz-Flores LG; Paez-Agraz F; Revicki DA
Arch Med Res; 2002; 33(6):572-80. PubMed ID: 12505105
[TBL] [Abstract][Full Text] [Related]
28. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Bilder RM; Goldman RS; Volavka J; Czobor P; Hoptman M; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Kunz M; Chakos M; Cooper TB; Horowitz TL; Lieberman JA
Am J Psychiatry; 2002 Jun; 159(6):1018-28. PubMed ID: 12042192
[TBL] [Abstract][Full Text] [Related]
29. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Purdon SE; Jones BD; Stip E; Labelle A; Addington D; David SR; Breier A; Tollefson GD
Arch Gen Psychiatry; 2000 Mar; 57(3):249-58. PubMed ID: 10711911
[TBL] [Abstract][Full Text] [Related]
30. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
[TBL] [Abstract][Full Text] [Related]
31. Amisulpride: a review of its use in the management of schizophrenia.
McKeage K; Plosker GL
CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
[TBL] [Abstract][Full Text] [Related]
32. [Prescription of olanzapine in children and adolescent psychiatric patients].
Frémaux T; Reymann JM; Chevreuil C; Bentué-Ferrer D
Encephale; 2007; 33(2):188-96. PubMed ID: 17675914
[TBL] [Abstract][Full Text] [Related]
33. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
34. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
Sauriol L; Laporta M; Edwardes MD; Deslandes M; Ricard N; Suissa S
Clin Ther; 2001 Jun; 23(6):942-56. PubMed ID: 11440294
[TBL] [Abstract][Full Text] [Related]
36. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
Laux G; Heeg B; van Hout BA; Mehnert A
Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
[TBL] [Abstract][Full Text] [Related]
37. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
38. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
[TBL] [Abstract][Full Text] [Related]
39. Olanzapine: a review of its use in the treatment of bipolar I disorder.
Bhana N; Perry CM
CNS Drugs; 2001; 15(11):871-904. PubMed ID: 11700151
[TBL] [Abstract][Full Text] [Related]
40. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
Revicki DA; Genduso LA; Hamilton SH; Ganoczy D; Beasley CM
Qual Life Res; 1999 Aug; 8(5):417-26. PubMed ID: 10474283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
